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OAketles. This study was conducted to determine the myocar-
dial beta-adrenoceptor density as a marker of sympathetic func-
tion in patients with hypertrophic cardionlyopathy and normal
control subjects .
Background. Although some cases of hypertrophic curdiainy-
opalby are familial with an aulosomal dominant pattern of
Inheritance, there remains a substantial proportion of cases in
which neither a family history nor genetic abnormalities can be
demonstrated. Additional abnormalities, both genetic and ac-
quired, may be important in the phenotypic expression of this
condition. Clinical features of the disease and metabolic studies
suggest an increased activity of the sympathetic nervous system .
Methods . Eleven patients with hypertrophic cardiomyopathy,
none of whom had previously received beta-blocking drugs, nad
eight normal control subjects underwent positron emission tomog-
raphy to evaluate regional left ventricular beta-adrenoceptor
density and myocardial blood flow using carbon-11 labeled CGP
12177 and oxygen-15-labeled water as tracers . Plasma catechola-
mines were also measured .
Although the majority of cases of hypertrophic cardiomyop-
athy are familial with an autosomal dominant pattern of
inheritance (1) and mutations of the beta-myosin heavy chain
gene in some families (2-4), neither a family history nor
genetic abnormalities can be demonstrated in a substantial
proportion of cases . In addition, some obligate carriers of
the genetic abnormality show no evidence of hypertrophic
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Results . Mean ( W) myocardial beta-adrenoceptor density
was significantly less in the hyperfrophic cardiomyopathy group
titan in the control group (7 .7ᆒ ± 1.86 vs . 11.5ᆒ d: 2.18 pmolᆒg
tissue, p < ᆒ.ᆒᆒ1). Myocardial blood flow was similar in
groups (ᆒ,91 ± ᆒ.22 vs . ᆒ .91 ± ᆒ.21 milmin per g, p = NS) . The
distribution of beta-adrenoreptor density was uniform throughout
the left ventricle in both groups . In the hypertrophic cardionty-
opathy group, there vas no correlation between regional wall
thickness and myocardial beta-adrenoceptor density . There were
no significant differences in either plasma norepinephrine or
epinephrine concenik allons between the two groups .
Conclusions . There is a diffm reduction in my dial beta-
adrenoceptor density in patients with hyperfrophic card yo thy
in the absence of significantly elevated circulating catecholamine
concentrations . This most likely reflects downregulatW of myocar-
dial beta-edrenoceptors secondary to increased myeartlial concen-
trations of norepinephrine and is consistent with the hypothesis that
cardiac sympathetic drive is increased in this condition .
(J Am Coda Cardiol 1993 ;22.1633-6ᆒ)
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cardiomyopathy, and there is considerable variation in the
clinical features of the disease between affected members of
the same family (5) . Thus, mutation of the beta-myosin
heavy chain gene may be neither necessary (6) nor sufficient
to explain the clinical and pathophysiologic features in all
patients with hypertrophic cardiomyopathy .
Some features of the disease, including left ventricular
hypercontractility (7), increased coronary vascular resis-
tance (8), a predisposition to tachyarrhythmias (7) and the
therapeutic efficacy of beta-blockers (9), suggest an in-
creased activity of the cardiac sympathetic nervous system .
Accordingly, an increased myocardial norepinephrine con-
tent (1ᆒ) as well as an elevated cardiac spillover of riorepi-
nephrine (11) have been demonstrated
in patients with
hypertrophic cardiomyopathy . Because changes in tissue or
circulating catecholamine levels -
are known to alter tissue
adrenoceptor density, we investigated possible abnormali-
ties of the sympathetic nervous system in patients with
hypertrophic cardiomyopathy by measuring circulating cat-
ᆒ735-1ᆒ97ᆒ931$6 .ᆒᆒ
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Tats
1. Symptoms and Echocardiographic Findings
in the Patients With Hypertrophic Cardiomyopathy
male; LVEDD - left ventricular end'diastolic diameter ; LVESD
echolamines and myocardial beta-adrenoceptor density in
vivo using positron emission tom phy .
Methods
Study patients . All subjects underwent preliminary
screening, which included a full history and clinical exami-
nation, electrocardiogram (ECG), echocardiogram and spi-
rometry. Subjects were excluded from the study if they
suffered from asthma, chronic bronchitis, diabetes mellitus
or an autoinimune disease. Women of childbearing years
were excluded
Patients with hyper1rophir cardiomyopathy . Eleven pa-
tients (mean age 37 ± 1ᆒ years ; 1ᆒ men) of a total of 12ᆒ
patients with hypertrophic cardiomyopathy attending Ham-
mersmith Hospital were identified as suitable for study and
all I I agreed to participate (Table 1) . Because treatment with
beta-blocking agents is known to affect myocardial beta-
awkenoceptor density, the main exclusion criterion of our
study was a current or past history of treatment with
beta-blockers . In addition, treatment with amiodarone alters
cell membrane composition and may therefore affect beta-
adrenoceptor density . Because the effects of amiodarone
persist for an undetermined period, we excluded all patients
who had previously taken amiodarone . In all I I patients, left
ventricular hypertrophy was asymmetric and was most
marked in the septum in 1ᆒ and in the lateral wall in 1 . All
were clinically stable and none had current or past evidence
of left ventricular failure, Four were being treated with
one with diltiazem and the remainder were re-
ceiviag no medication. Administration of all drugs was
stopped 3 days before the study .
Control subjects. This group consisted of eight normal
volunteers (mean age 28 ± 7 years ; all men) . None had any
evidence of cardiovascular disease . AN had a normal rest
ECG and echocardiogram
. All subjects gave written in-
funned consent to a protocol approved by the Hammersmith
left ventricular end"Yoolic diameter ; M a, male ; Pt - patient.
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Hospital Research Ethics Committee and the United King-
dom Administration of Radioactive Substances Advisory
Committee .
Study protocol . Patients and control subjects fasted for
-z6 h before the study. All studies were performed at the
same time of day between 2 Pm and 6 PM . One 18G cannula
was inserted into a large forearm vein for the purposes of
blood sampling and a second 21G venous cannula into the
other arm for the drug infusions . Arterial blood pressure
measured by cuff sp!Iygmomanometry and a standard
12-lead surface ECG were recorded at 1ᆒ-min intervals
throughout the study . Four serial blood samples for mea-
surement of plasma catecholamine levels were taken with
the subject in the supine position at baseline (=tN min after
the insertion of the venous cannula) and at 3ᆒ,6ᆒ and 9ᆒ min
thereafter. Twenty microliters of a solution containing 6%
glutathione and 9 .5% ethylene glycol tetraacetic acid were
added per ml of blood . Samples were centrifuged immedi-
ately and plasma was stored at -7ᆒ'C for later assay.
Positron emission tomography (PET) . The subject was
positioned on the bed of an ECAT 931-ᆒ8ᆒ12, 15-plane
positron tomograph (SiemensᆒCTI Inc .) so that the left
ventricle lay as close as possible to the center of the axial
and transaxial fields of view. Before performing the emission
study, a circular ring source filled with about 2 mCi of
germanium-68 was used for the blank and transmission data
acquisition. Initially, a rectilinear transmission scan was
recorded and used as a low resolution X-ray film to identify
the heart profile. A transmission scan was then recorded for
a 2ᆒ-min period to measure the attenuation correction co-
efficients to be used for each line of response of the emission
sinogram .
Blood volume scan . A blood volume scan was obtained
using inhaled oxygen-l5-labeled carbon monoxide (C 15ᆒ) .
Four serial venous samples were taken during the ᆒᆒ scan
and counted in a calibrated well counter (12) .
Echocardiographic Variabies
Pt
No .
Age (yrY
Gender
Chest
Pain Dyspnea Syncope Palpitation
Maximal
Thickness
(mm)
Minimal
Thickness
(mm)
LVEDD
(mm)
LVESD
(mm)
Fractional
Shortening (%)
33ᆒM Yes Yes No Yes 21
1ᆒ 51 3ᆒ 41
331M No Yes No
Yes 23 12 47 31 34
3 47ᆒF Yes Yes
Yes Yes 17 14 4ᆒ 2ᆒ 5ᆒ
4 3?JM Yes No No Yes 23
8 36 2ᆒ 44
5 361M No No Yes No
31 14 4ᆒ 25 37
6 511M No No No
No 17 12 47 3ᆒ 36
WM No No No No 16 13
24 52
2ᆒM Yes No No No 27
II 44 27 39
9 AM Yes No Yes Yes
15 11 46 34 26
1ᆒ 27ᆒM No No No No
15 1ᆒ 46 32 3ᆒ
I I 49ᆒM No No No No 17
14 54 38 3ᆒ
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Myocardial blood flow scan . Regional myocardial blood
flow was subsequently measured using oxygen-l5-labeled
water (H,' 5ᆒ) from inhaled oxygen- 15-labeled carbon diox-
ide (C' -'ᆒ2) as described elsewhere (12) .
Beta-adrenoceptor density scan . Measurement of myo-
cardial beta-adrenoceptor density was performed according
to a modification of the double-injection method of Delforge
et al. (13). The carbon-1 I-labeled S-enantiomer of the non-
selective hydrophilic beta-blocker CGP 12177 (S-["C]CGP
12177) was prepared as previously described (14) and used as
a high affinity radioligand to quantify myocardial beta-
adrenoceptor density . A first dose of S-["C]CGP 12177 with
high specific activity (7,2 ± 1 .9 pg ST'CJCGP 12177 ; 155 ±
33 MBq; specific activity 6 .4 ± 1 .9 Gl3qᆒAniol) was infused
intravenously over 2 min, followed 3ᆒ min later by a second
dose with low specific activity (34 .5 ± 4 .5
pg
S-["C]CGP
12177 ; 324 ± 148 MBq ; specific activity 2 .4 ± ᆒ.7 68qᆒAniol)
infused intravenously over 2 min . A 45-frame dynamic
emission scan was used to define the temporal and spatial
distribution of the tracer in vivo . A single 3ᆒ-s background
frame was acquired before the intravenous infusion of the
first dose of ST'QCGP 12177 . During the 3ᆒ-min period
after the start of the first infusion of S-["C]CGP 12177,
22 time frames (8 x 15, 4 x 3ᆒ, 2 x 6ᆒ, 2 x 12ᆒ, 4 x 15ᆒ and
2 x 3ᆒᆒ s) were acquired. The second injection of
S-["C]CGP 12177 was then given and scan data were
acquired according to an identical sequence of time frames .
Nineteen timed venous blood samples were collected during
the S-["C]CGP 12177 scan for later correction for vascular
activity of the tracer .
Reproducibility of positron emission tomographic mea-
surements . To assess the reproducibility of the measure-
ments of myocardial blood flow and beta-adrenoceptor den-
sity, a repeat tomographic scan was performed in four
patients under comparable conditions within 127 ± 18 days
of the first study .
Positron emission tomographic data analysis . Sinograms
were normalized, corrected for attenuation and then recon-
structed to provide images with a transaxial spatial resolu-
tion of 8.4 mm full width at half maximum and a slice
thickness of 6.6 mm full width at half maximum . Data
collection and initial processing were performed using ded-
icated array processors on a MicroVax 2 computer (Digital
Equipment Corp .). The final images were transferred to
SUN 3ᆒ6ᆒ workstations (Sun MicroSystems) for further
analysis by use of Analyze image analysis (Mayo Founda-
tion) and Pro-Matlab (The Math Works, Inc .) mathematical
software packages .
Calculations of blood volume and regional myocardial
blood flow . Regional values of blood volume (VB ml
bloodᆒml region of interest) were obtained by relating equi-
librium images of the C 15 ᆒ distribution to the radioactive
concentration of venous blood samples during the scan .
Corrections were made for radioactive decay and blood
density (1 .ᆒ6 glad). In each of the five adjacent scan planes
being analyzed, which encompassed most of the left ventric-
LA
2ᆒ 4ᆒ
L
6ᆒ 8ᆒ
Time(min)
Figure 1 . Typical myocardial time-activity curve obtained after a
high specific activity (HSA) and a second low specific activity (LSA)
injection of S-I"CJCGP 12177 in a normal subject .
tiler myocardium, four different regions of interest corre-
sponding to anterior, lateral, inferoposterior and septal myo-
cardium were selected . The mean left ventricc?ar myocardial
blood flow was obtained by defining a further region of
interest that encompassed the entire left ventricle within the
five adjacent scan planes. Myocardial blood flow (mlᆒmin per
g) for each region of interest was calculated by fitting the
arterial input (obtained from a left atrial region of interest)
and tissue time-activity curves from the blood flow scan to a
single tissue compartment tracer kinetic model as previously
described (12) . This model includes corrections for the
underestimation of tissue activity due to the partial volume
effect and the spillover of activity from the left ventricular
chamber into the myocardial region of interest .
Calculation of myocardial beta-adrenoceptor density .
The same regions of interest that had been used to calculate
myocardial blood flow were then applied to the S-["C]CGP
12177 scan . The myocardial tracer time-activity curves were
corrected for radioactive decay and for vascular activity
using the regional values of blood volume (V B) and the
radioactive concentrations of blood samples taken through-
out the dynamic scan . The sections of the curve correspond-
ing to the two slow phases, which represent S-["C]CGP
12177 bound to beta-adrenoceptors, were exponentially ex-
trapolated on the y axis back to the start of the infusions
(Mg. I ) . The beta-adrenoceptor density was derived from the
maximal number of available specific S-["C]CGP 12177
binding sites per gram of tissue (Bmax) in the region of
interest
. Values for the maximal number of available specific
S-["C]CGP 12177 binding sites per gram of tissue were
calculated using a modification of the equation derived by
Delforge et al . (13) to take account of the molar content of
S-CGP 12177 in both injections . In addition, the values for
the maximal number of available specific S-["C]CGP 12177
binding sites per gram of tissue were corrected for the partial
volume effect by normalizing to the extravascular tissue
volume (ml tissue per ml of region of interest), obtained by
subtracting vascular density image from the normalized
transmission scan (15). To convert the myocardial blood
flow and beta-adrenoceptor density values from units per ml
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Table 2. Regional Beta
. kdrenoceptor Density, Myocardial Blood Flow and Perfusable Tissue
Index in Patients With Hypertrophic
Cardiomyopathy (HCM) and Control Subjects
of tissue to units p4 :r grarn of tissue, all final values were
divided by 1 .ᆒ4 (mytxardial tissue density)
Calculation of the pertusable tissue index . This is de-
fined as the proportion of tissue within a given region of
interest that is capable of rapidly exchanging water and has
units of gms of perfusable tissueᆒgrams of total anatomic
tissue (16) . A normal value indicates that all the myocardium
within that region of interest is readily perfusable . A low
value (<ᆒ.6) indicates substantial loss of readily perfused
tissue and is associated with permanent loss of contractile
function (16) .
Plasma catecholamine assay. Plasma catecholamines
(epinephrine and norepinephrine) were determined within 2
months of blood sampling by an adaptation of the method
described by Bouloux et al. (17) using high performance
liquid chromatography with electrochemical detection, Stan-
daW samples of catecholamines were obtained by dissolving
epinephrine bitartrate and norepincphrine bitartrate in ᆒ.1 M
hydrochloric acid and adding small volumes of the solution
to plasma to obtain final concentrations of ᆒ .1, ᆒ .25, ᆒ.5,
1 mW 3 ngᆒml . The limit of detection for epinephrine was
ᆒ.ᆒ5 nolml and that for norepinephrine ᆒ .18 ngᆒml .
All values are expressed as mean ± SD. Anal-
ysis of variance (split-plot ANOVA) (18) was carried out to
assess the consistency of differences in beta-adrenoceptor
density and myocardial blood flow among the myocardial
regions of interest in the patient and control groups (group
by region interaction) . Two-tailed unpaired t tests were used
to compare: the values of myocardial beta-adrenoceptor
density and myocardial blood flow between the two study
ps. Two-way repeated measures analysis of variance of
ft logarithmically transformed values of the plasma cate-
eholamine concentrations was used to detect any significant
time-dependent effect and any differences between the two
study gmwps . Linear regression analysis was used to analyze
the relation between plasma catecholaminc concentrations
and myocardial beta-adrenoceptor density . A p value < ᆒ.ᆒ5
was considered statistically significant .
Op < ᆒ.ᆒ1 and tp < ᆒ .ᆒ5 . compared with values in control subjects
.
Results
Myocardial beta-adrencteeptor density . Regional myocar-
dial beta-adrenoceptor density was uniform throughout the
left ventricle in both groups (`Table 2). Within each group,
there was no significant base to apex gradient in myocardial
beta-adrenoceptor density. The mean myocardial beta-
adrenoceptor density was significantly lower in the patients
with hypertrophic cardiomyopathy than in control subjects
(7.7ᆒ t 1 .86 vs. 11 .5ᆒ ± 2.18 pmoUg tissue, p < ᆒ.ᆒᆒ1 ;
Fig. 2). In patients with hypertrophic cardioinyopathy, the
myocardial beta-adrenoceptor density in the most hypertro-
phied region was not significantly different from that in the
least hypertrophied region (Fig. 3). Beta-adrenoceptor den-
sity did not correlate with the plasma concentration of
norepinephrine or epinephrine .
flow. Regional myocardial blood flow was
uniform throughout the left ventricle in both groups (Table 2) .
There were no base to apex gradients in myocardial blood flow
Flilare 2 . Individual
values
of meter myocardial beta-adrenoceptor
density in the patients with hypertrophic cardiomyopathy (HCM)
and control subjects
. The mean values of each group are indicated
by the bainatal lines .
W~11
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Region
Anterior Lateral Posterior Septal
Myocardial beta-adrenoceptor density
(pmoys tissue)
Patients with Hem 6.8 1s*
7.9 ± 23* 7.8± 3At
8.5±2.3*
Control subjects
11 .3 3 .2 12 .1 ± 2.6 111ᆒ.9±2.9 12A±2,4
Myocardial blood flow
(MIᆒmin per g tissue)
Patients with Hem ᆒ.89±ᆒ.22 1 .ᆒ5±ᆒ.28 1
.ᆒ7±ᆒ.5ᆒ ᆒ.84±ᆒ.2ᆒ
Control subjects ᆒ.92 ± ᆒ13 ᆒ,96 t ᆒ.24
ᆒ19 t ᆒ .26 ᆒ.85 ± ᆒ.24
Perfusable tissue index
(g perfusable tissooᆒI total anatomic tissue)
Patients with Hem 1 .ᆒ9 ± ᆒ .ᆒ4
1.ᆒ5±ᆒ.ᆒ7 1.ᆒ2±ᆒ.1ᆒ 1.15±ᆒ.ᆒ9
Control subjects 1 .ᆒ4 ± ᆒ
.11 1 .ᆒ5 ± ᆒ.ᆒ5 1 .ᆒ3 ± ᆒ.12 1 .21 1 kit
15
ᆒ
ᆒ
ᆒ
ᆒ
7 (;61
1ᆒ
I
ᆒ
ᆒ
5
ᆒ
ᆒ
ᆒ
HCM Controls
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Maximal
	
Minimal
hypertrophy hypertrophy
Figure 3 . Myocardial beta-adrenoceptor density in the regions of
maximal hypertrophy compared with that front the regions with
minimal hypertrophy in the patients with hypertrophic cardiomyopa-
Oy,
measured in the five adjacent scan planes . Mean myocardial
blood How did not differ significantly between patients with
hypertrophic cardiomyopathy and the control subjects (ᆒ .91
ᆒ.22 vs . ᆒ.91 ± ᆒ .21 mlᆒmin per g, p = NS) .
Perfusable tissue index. The regional perfusable tissue
index in the two groups was comparable (Table 2) . Mean
perfusable tissue index in the patients with hypertrophic
cardiomyopathy was similar to that in the control subjects
(1 .ᆒ8 ± ᆒ.ᆒ5 vs. 1 .ᆒ5 ± ᆒ.ᆒ8 g perfusable tissueᆒg total
anatomic tissue). This finding confirmed that there was no
significant replacement of myocytes with fibrous scar tissue
in these patients with hypertrophic cardiomyopathy . In both
groups, the perfusable tissue index was higher in the septum
than in the other regions. This effect has been observed
previously (16) and is considered to be due to spillover of
activity from the right ventricular blood pool .
Reproducibility of positron emission tomographic measure-
meats . The average variability of myocardial blood flow
between the two measurements (baseline and repeat scan in
four patients) was 16 ± 7% and that for beta-adrenoceptor
density 17 t 8% . Thus, the reproducibility of both flow and
beta-adrenoceptor density measurement was >8ᆒ% .
Plasma catecholamine levels . There was no significant
difference between the patients with hypertrophic cardiomy-
opathy and control subjects in the initial plasma concentra-
tions of norepinephrine (ᆒ.93 ± ᆒ.38 vs . ᆒ.77 ± ᆒ.19 ngᆒml,
p NS) and epinephrine (ᆒ.4ᆒ ± ᆒ.19 vs. ᆒ.27 t ᆒ.ᆒ9 ngᆒml,
p NS) before the first injection of S-["C]CGP 12177 .
There was no significant change in plasma concentration of
either norepinephrine or epinephrine after the two injections
of S-["C]CGP 12177 or in the fourth sample obtained at the
end of the study. The mean values over the four sampling times
of the plasma norepinephrine and epinephrine concentrations
for each subject were ᆒ .79 ± ᆒ.2ᆒ vs . ᆒ .76 ± ᆒ .23 ngtmI (p =
NS) for norepinephrine and ᆒ .39 ± ᆒ.13 vs . ᆒ .28 ± ᆒ.ᆒ7 ngᆒml
(p = NS) for epinephrine (patients with hypertrophic cardio-
myopathy vs . normal subjects, respectively) .
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Discussion
The major finding of this study is that myocardial beta-
adrenoceptor density is significantly reduced in patients with
..ypertrophic cardiomyopathy compared with that in normal
subjects despite comparable levels of circulating catechol-
amines . This observation suggests a specific increase in the
activity of the cardiac sympathetic nervous system. Three
considerations lend particular strength to the present study in
comparison with previous reports (19-21) that assessed beta-
adrenoceptor density in hypertrophic cardiomyopathy . 1) Truly
normal volunteers were studied as control subjects . 2) No
patient had ever received beta-blocker or amiodarone therapy .
3) The technique used gives regional measurements of adreno-
ceptor density, which is of particular interest in this condition
because the macroscopic abnormality is strikingly nonuniform .
Myocardial beta-adrenoceptors in hypertrophic cardiomy-
opathy . Golf et al . (19) measured myocardial beta-
adrenoceptor density by in vitro radioligand binding in 5
patients with hypertrophic cardiomyopathy and in a control
group of 1ᆒ patients with various types of heart disease . In
contrast to our findings, they found no difference in myocar-
dial beta-adrenoceptor density between these two groups .
However, in their study, there was no normal control group
and two of the patients with hypertrophic cardiomyopathy
were taking beta-blockers, which are known to cause upreg-
ulation of beta-adrenoceptors (22) . In their patients with
hypertrophic cardiomyopathy (19), the biopsy specimens
were always taken from the interventricular septum,
whereas in three patients in their control group biopsy was
performed from the left ventricular papillary muscle and in
three other control subjects from the right ventricular out-
flow tract . Similarly, Ferry and Kaumann (2ᆒ) found no
difference in myocardial beta-adrenoceptor density in left
ventricular biopsy samples from patients with hypertrophic
cardiomyopathy compared with those from patients with
mixed mitral valve disease, but again there was nu iiuitiwi
control group . Wagner et al. (21) showed that beta-
adrenoceptor density in atrial tissue obtained from patients
with hypertrophic cardiomyopathy was similar to that in
patients with various other cardiac diseases, some of whom
had left ventricular failure, which is known to be associated
with beta-adrenoceptor downregulation (23) .
Thus, interpretation of previous studies (19-21) in which
myocardial beta-adrenoceptor density has been evaluated is
complicated by the lack of information from biopsy !;pcci-
mens from normal hearts. These studies used patients with
other forms of heart disease as control subjects . It is
possible, although it has not been reported, that beta-
adrenoceptor downregulation may occur in many cardiac
diseases, not just in those associated with the clinical syn-
drome of heart failure
. In addition, in two of these studies
(19,2ᆒ), the biopsy sites in the hypertrophic cardiomyopathy
group and the control group were different . In the third study
(21), the use of atrial rather than ventricular myocardium for
the measurements may explain why no difference was seen .
JACC Vol . 22, No . 6
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Finally, in all three studies (19-21), there may have been
confounding effects from the treatment that the patients
were receiving
. Several of the patients were receiving beta-
blockers or amiodarone
. Beta-blocker therapy is known to
upregulate beta-adrenoceptor density (22), and even the dis-
continuation of treatment for 1 week before tissue was ob-
tained (2ᆒ) may have allowed insufficient time for return to the
basal state . Wagner et al. (21) noted that the three patients who
had been treated with amiodarone had the lowest density of
calcium antagonist binding sites even though they had stopped
taking amiodarone 2 .5 to 17,5 weeks before tissue sampling .
Thus, it is conceivable that ami ne may also have affected
bet hadrenoccptor density in these three patients, although this
was not reported (21) . Our study is therefore unique in that we
included a normal control group and excluded patients who had
received beta-blockers or amimdarone therapy at any time in
the past.
We consider that our observation reflects a real difference
in betaadrenoceptor density on the cardiac myocytes in
patients with hypertrophic cardiomyopathy . However, there
are two possible alternative explanations for our findings .
1) The myocardial beta-adrenoceptor density in the patients
with hypertrophic cardiomyopathy might be reduced as a
consequence of a low surface arealvolume ratio of the hyper-
trophied myocytes . This is an unlikely explanation because it
does not explain the observation that myocardial beta-
adrenoceptor density is low even in the nonhypertrophied
regions of the left ventricle, and there is no correlation between
the degree of hypertrophy and the reduction in beta-
adrenoceptor density in the asymmetrically hypertrophied
myocardium. 2) It is possible that the beta-adrenoceptor den-
sity on the myocytes is normal but that the proportion of
cardiac myocytes relative to the other tissue components (for
example, fibrous tissue) is reduced in hypertrophic cardiomy-
o y. However, all of our patients had unimpaired left
ventricular systolic function (Table 1) and the pert'usable tissue
index was bit to that in the control group in each
region (Table 2), ruling out the presence of substantial myocar-
dial scarring. Thus, we consider that "dilution" of cardiac
myocytes by nonmyocyte tissue could account at most for only
a small part of the observed difference .
Other factors may affect the beta-adrenoceptor density,
and one such reported factor is age (24) . Although age would
not have had a significant impact on the difference between
the Mean values of beta-adrenoceptor density in the two
study groups, because the mean ages of the two groups were
not different, it might have increased the variability within
the groups . In addition, the downregulation of myocardial
beta-adrenoceptor density that we observed in patients with
hype p hic cardiomyopathy may have been an underesti-
mate because we excluded patients with severely symptom-
atic manifestations of the condition who were taking beta
bl drugs or amiodarone . Thus, although there was
some overlap in the individual values of beta-adrenoceptor
density between the groups (Fig
. 2), we consider that our
finding does represent an important underlying difference
between the patients with hypertrophic cardiomyopathy and
the normal subjects .
Potential mechanisms for the reduced beta®adrenoceptor
density. Receptor downregulation occurs as a consequence
of increased agonist activity, and this is likely to be the
mechanism for the reduced beta-adrenoceptor density in our
patients. Kawai et al. (1ᆒ) measured myocardial norepineph-
rine levels in right and left ventricular endomyocardial
biopsy specimens from patients with hypertrophic cardiomy-
opathy and control subjects without cardiomyopathy . They
showed that right ventricular myocardial norepinephrine
levels were similar in patients and control subjects and that
the serum norepinephrine and epinephrine levels were also
comparable in the two groups . The myocardial norepineph-
rine levels were high in left ventricular biopsy samples from
12 patients with hypertrophic cardiomyopathy compared
with values in control subjects and in a third group of six
patients who had congestive cardiomyopathy . Their study
(1ᆒ) is limited because the control group comprised patients
with a variety of cardiac diseases and left ventricular biopsy
specimens were obtained in only two control subjects . More
recently, Brush et al . (11) reported an increased cardiac
arteriovenous difference in norepinephrine concentration in
patients with hypertrophic cardiomyopathy and provided
evidence that this was due to impaired neuronal uptake and
metabolism of norepinephrine . This abnormality would in-
evitably result in elevated myocardial norepinephrine levels
effective at the adrenoceptors, although these were not
measured directly (11) . Thus, our observation of a reduced
myocardial beta-adrenoceptor density in patients with hy-
pertrophic cardiomyopathy may be the result of receptor
downregulation secondary to chronically elevated myocar-
dial norepinephrine concentrations .
Hypcrtrophic cardiomyopathy may be associated with ele-
vated total myocardial norepinephrine content (1ᆒ), whereas in
heart failure total myocardial norepinephrine content is re-
duced (25). However, the total myocardial norepinephrine
content does not necessarily reflect the effective concentration
of norepinephrine at the adrenoceptors . The reduced total
myocardial norepinephrine content that is observed in heart
failure may simply reflect depletion of neuronal stores . This
would be consistent with a high rate of myocardial norepineph-
rine turnover, and depleted stores may still be associated with
maintained or increased norepinephrine release .
Neither we nor others (1ᆒ) have found significantly in-
creased levels of circulating catecholamines in patients with
hypertrophic cardiomyopathy . The norepinephrine concen-
tration in our control group was similar to that measured by
others (26) in normal subjects . It remains possible that we
missed a statistically significant difference in the plasma
epinephrine concentrations between the two groups because
of the number of subjects included in the study . The mean
plasma concentrations of norepinephrine and epinephrine
were 5% and 42% higher, respectively, in the patients with
hypertrophic cardiomyopathy compared with the normal
subjects. For comparison, plasma norepinephrine and epi-
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nephrine levels were markedly increased (127% and 387%,
respectively) in patients with congestive cardiomyopathy (1ᆒ),
a condition known to be associated with beta-adrenoceptor
downregulation (27) . The degree of beta-adrenoceptor down-
regulation that we observed in patients with hypertrophic
cardiomyopathy (33%) is similar to that found in patients with
heart failure (38%) associated with a moderately impaired left
ventricular ejection fraction of ᆒ .25 to ᆒ .5ᆒ (27) . Thus, it is
probable that comparable degrees of myocardial beta-
adrenoceptor downregulation in patients with hypertrophic
cardiomyopathy and patients with moderately severe heart
failure are associated with much lower circulating plasma
catecholamine concentrations in patients with hypertrophic
cardiomyopathy than in patients with heart failure . We con-
clude that the observed decrease in beta-adrenoceptor density
in our study is due mainly to increased myocardial levels of
norepinephrine derived from cardiac sympathetic nerves rather
than to increased circulating catecholamine concentrations,
and this view is consistent with the findings of others (1ᆒ, 11) .
Local rather than systemic mechanisms have also been inipli-
cated in the beta-adrenoceptor downregulation observed in
patients with heart failure (25)
Implications of our study . Many cases of hypertrophic
cardiomyopathy are familial and, in some kindreds, mutations
of the beta-cardiac myosin heavy chain gene have been iden-
tified (2,3) . This makes it unlikely that an abnormality of the
sympathetic innervation of the heart is the prime mover in the
pathogenesis of this condition . However, it is probable that
there is a secondary alteration in myocardial norepincphrinc
metabolism and that this may mediate the development and
maintenance of cardiac hypertrophy . There is strong experi-
mental evidence (28) that myocardial hypertrophy can be
induced by alpha- and beta-adrenergic stimulation in animal
models and that this is a direct action on cardiac myocytes with
increased expression of genes for contractile proteins and
increased protein synthesis with myocyte hypertrophy . These
effects are independent of increased hemodynamic load . The
obvious implication is that aggressive sympathetic blockade
not only offers a potential mechanism for the relief of symp-
toms of hypertrophic cardiomyopathy, but also may attenuate
the development of myocardial hypertrophy or even lead to
regression . There is preliminary evidence (29) in support of this
view from a group of infants, children and adults with severe
manifestations of hypertrophic cardiomyopathy in whom treat-
ment with high dose propranolol led to regression of hyper-
trophy.
Beta-blocker therapy leads to beta-adrenoceptor upregu-
lation (22) and may be beneficial in patients with heart failure
(3ᆒ,31) . Similarly, serial measurements of beta-adrenoceptor
density in patients with hypertrophic cardiomyopathy may
enhance our understanding of the mechanisms by which
beta-blocking drugs are effective in these patients .
Methodologic considerations . Positron emission tomogra-
phy is a well established method for the quantitative, non-
invasive measurement of regional myocardial radionuclide
distribution in vivo . This technique has been used for the
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quantitation of regional myocardial blood flow (8,12), metab-
olism (32) and recently beta-adrenoceptor density (33) . The
hydrophilic beta-adrenoceptor antagonist CGP 12177 labeled
with "C (["C]-CGP 12177) is an ideal ligand for the mea-
surement of total beta-adrenoceptor density because it has a
high affinity, is nonselective and hydrophilic, does not cross
the cell membrane and therefore binds only to the function-
ally active cell surface receptors (34-36) . After injection of
[ 3 H]CGP 12177 into rats, it binds to specific sites from which
it can be displaced by propranolol (37) . Metabolism of CGP
12177 during the time course of this protocol would be
expected to be insignificant, with >97% remaining un-
changed at 6ᆒ rain after intravenous injection in humans (38) .
Quantitation of beta-adrenoceptors in humans has previ-
ously been carried out using in vitro radioligand binding to
membrane preparations from endomyocardial or surgical
biopsy samples or from explanted hearts, and results are
expressed as fmolᆒmg of protein (22,27,39) . Myocardial
beta-adrenoceptor density estimated by these in vitro studies
has been found to be in the range of 35 to 15ᆒ hnolᆒmg of
protein, which is comparable to the PET-derived values
in the present study because tissue protein content is
approximately 1ᆒ% (4ᆒ) . Moreover, Merlet et al . (26) re-
ported a significant correlation between left ventricular
beta-adrenoceptor density measured by PET with ["C]CGP
12177 and beta-adrenoceptor density measured using in vitro
binding of a3 HICGP 12177 in left ventricular endomyocardial
biopsy specimens taken from eight patients with idiopathic
dilated cardiomyopathy (r = ᆒ .79, p = ᆒ.ᆒ19) . This is a
remarkably good correlation in light of the fact that the two
methods do not make directly comparable measurements for
several reasons . 1) Beta-adrenoceptor density in the suben-
docardium is known to be different from the average for the
entire myocardium in some patients (39) . 2) Positron emis-
sion tomography with ["C.]CGP 12177 measures only the
functional cell surface receptors because CGP 12177 is
hydrophilic, does not cross the cell membrane and does not
therefore bind to internalized receptors (35). In contrast, in
vitro binding studies on biopsy specimens involve tissue
homogenization, which exposes the internalized receptor
pool to the ligand . This consideration implies that PET with
[I IC]CGP 12177 is a more physiologically relevant measure-
ment of the beta-adrenoceptor density than the measure-
ments obtained from biopsy specimens . 3) Positron emission
tomography with ["C]CGP 12177 gives a measure of beta-
adrenoceptor density per ml in the region of interest, whereas
in vitro measurements are corrected for tissue protein .
We restudied four of the patients with hypertrophic
cardiomyopathy 127 ± 18 days after the first study . The
variability of the measurements of regional left ventricular
myocardial beta-adrenoceptor density was 17 t 8%
. This
represents 51% of the difference between the two study
groups . The reproducibility of the technique was >8ᆒ .
Conclusions . Myocardial beta-adrenoceptor density is re-
duced in hypertrophic cardiomyopathy, and this reduction is
most probably a reflection of abnormal cardiac sympathetic
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nerve function . Further evaluation of the role of abnormal
sympathetic function in the generation and maintenance of
cardiac hypertrophy in this condition may lead to the devel-
opment of rational strategies to modulate sympathetic func-
tion and thereby improve the clinical outcome .
We express our gratitude to the Radiochemistry
Department of the MRC
Cyclotron Unit for the preparation of radiotracers
and to Claire Taylor,
Andreanna Williams and Grahame Lewington for their assistance
in perform-
ing the studies
. We also thank Patrick Royston, BSc (Department of Medical
Physics, Royal Postgraduate Medical School) for statistical
advice .
References
I, Gilllpn DM, Cleland JGF, Oakley CM
. The genetics of hypertrophic
carp,ionivopathy . Br heart 11991-,66 :193-5,
2, Taiallawa ᆒ, Jarcho JA
. Kegs S, et al . A molecular basis for familial
hypertrophic cardiomyopathy
: an alphaᆒbeta cardiac myosin heavy chain
hybrid gene, Cell 199M.62,9914
3. Geisterfer-Lowrence AA, Kass S, Tanigawa G, et al
. A molecular basis
for familial hypertrophic cardiomyopathy : a beta cardiac myosin heavy
chain missense mutation . Cell 199ᆒ ;62 :999-1ᆒᆒ6 .
4, Watkins H, Rosenzweig A, Hwang D-S, et al . Characteristics and
prognostic implications of myosin missense mutations
in familial hyper-
trophic cardiomyopathy . N EngI J Med 1992;326
:11ᆒ8-14 .
5 . Epstein ND, Lin HJ, Fananapazir L . Genetic evidence of dissociation
(generational skips) of electrical from morphological forms of hyper-
trophic cardiomyopathy. Am J Cardiol 199ᆒ ;66:627-3 1 .
6 . Schwartz K, Beckmann J, Dufour C, et al . Exclusion of cardiac myosin
heavy chain and actin gene involvement in hypertrophie ordiomyopathy
of several French families . Circ Res 1992 -.71 :3-8.
7 . Maron BJ, Bonow RO, Cannon Ill RO, Leon MB, Epstein SE. Hyper-
trophic cardiomyopathy : interrelations of clinical manifestations, patho-
physiology, and therapy. N Enill J Med 1987,316 ., 78ᆒ-9, 844-52 .
8 . Camici P. Chiriatti ᆒ, Lorenzoni R, et W . Coronary vasodilation is impaired
in both hypertrophied and northypertrophied myourdium of patients with
hypedrophic cardiomyopathy : a study with nitrogen-13 ammonia and
positron emission tomography, J Am Coll Cwdiol 1991,17,879-86 .
9. Cohen LS, Braunwaid F, Amelioration of angina pectoris in idiopathic
hypeArophic subaortic stenosis with beta-adrenergic
blockade. Circula-
tion 1967ᆒ5 .847-51,
It Kawai C, YW Y, Hoslino T, Uayama S . Matiumori A. Myocardial
cat fines in hypertrophic and dilated (congestive) cartliomyopathy
:
a biopsy study, J Am Coil Cardiol 191131834-4ᆒ .
IL Brush X Eisenhofer ᆒ, Garly M, et al, Cardiac norepinephrine kinetics
in hypertrophic cardiomyopathy . Circulation 11989-.791M-44,
12
. Ainuo LI, Lammerlmina AA, Rhodes ᆒ1 ᆒ al, Noninvasive quantifica-
tion of Pqtonal myocardial blot flow in coronary artery
disease with
oxygen-154"ed carbon dioxide inhalation and positron emission
tomography . Circulation 1991,83,875-85 .
13, Delidge J4 Syrota A, Lancon JP, et al, Cardiac bewadrenergic receptor
density measured
in vivo using PET, COP 12177, and a new graphical
method, I Noel Med 1991 ;32.739-48.
14. Brady F, Luthra SK, Todnon-Davy H,
et al. Asymmetric synthesis of
a precursor for the automated radiosynthesis of S1 11C]COP 12177 as a
preferred radioligarall for the p-adrenergic
receptors . Appl Radial Isot
1991,42121-8,
IS, lids H, Rhodes CG, de Silva R, et al,
Myocardial tissue fraction:
Correction for partial volume effects and
measure of tissue viability.
J Noel Med 1"ᆒ21169-75,
I& 176111amoto
Y,
de Silva R, Rhodes CO, e al .
A new strategy for the
Umwmt of viabic myocardium and regional myocardial
blood flow
uuw `O-water and dynamic positron emission tomography
. Circulation
19X;86 :167-78,
17, BOubu P, Perrett D, Besser GM
. Methodological considerations in the
determination, of plasma catecholamines by high performance liquid
CbfOwogr*Y with electrochemical detection. Ann Olin Biochem 1985
;
22 :194-2ᆒ3
.
18. Snedecor GW, Cock an WG
. Statistical Methods. Ames, IA: University
of Iowa Press, 1967 :369-73 .
19
. Golf S, Myhre E, Abdelnoor M, Andersen D, Hansson V . Hypertrophic
cardiomyopathy characterised by ᆒ3-adrenoceptor density, relative
amount of P-adrenoceptor subtypes and adenylate cyclase activity . Car-
diovasc Res 1985,19:693-9.
2ᆒ . Ferry DR
. Kaumann AL Relationship between ᆒ3-adrenoceptors and
calcium channels in human ventricular myocardium . Br J Pharmacol
1987 ;9ᆒ:447-57
.
21 . Wagner JA, Sax FL, Weisman HF, et al . Calcium-antagonist receptors in
the atrial tissue of patients with hypertrophic cardiomyopathy . N Engl J
Med 1989;32ᆒ:755-61 .
22 . Heilbrunn SM, Shah P, Bristow MR, Valentine HA, Ginsburg R, Fowler
MB. Increased j&receptor density and improved hemodynamic response
to catecholamine stimulation during long-term metoprolol therapy in heart
failure from dilated cardiomyopathy
. Circulation
1989
;79:483-9t
23. Bristow MR. Ginsburg R, Minobe W, et al . Decreased catecholamine
sensitivity and P-adrenergic receptor density in failing human hearts .
N Engl I Med 1982;3ᆒ7:2ᆒ5-11
24, White M . Wollmering MM, Handwerger ᆒ, Klein J
. Larrabce P, Bristow
MR
. Age related changes in beta I and beta 2 adrenergic receptors and
adenylate cyclase stimulation in nonfailing and failing human hearts
[abstrac(l
. J Am Coll Cardiol 1992,19Stippi A. 194&
25. Bristow MR. Minohe W, Rasmussen R, et al . Beta-adrenergic neuro-
effector abnormalities in the failing human heart are produced by local
rather than systemic mechanisms . J Clin Invest 1992:89 :8ᆒ3-15 .
26
. Merlet P, Delforge J, Syrota A, et al . Positron emission tomography with
11 C COP-12177 to assess beta-adrenergic receptor concentration in
idiopathic dilated cardiomyopathy
. Circulation 1993
;87:1169-78 .
27. Fowler MB. Laser JA, Hopkins GL, Minobe W, Bristow MR . Assess-
ment of the p-adrenergic receptor pathway in the intact failing human
heart: progressive receptor downregulation and subsensitivity to agonist
response . Circulation 1986 ;74 :129ᆒ-3ᆒ2 .
28. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural and
endocrine dependence
. Circulation 1991-,83:13-25.
29. Ostman-Smith 1 . Regression of cardiac byperfrophy achieved by high
dose propranolol treatment in children
and adults with hypertrophic
cardiomyopathy lab matt] . Br Heart J 1991 ;66 :76 .
3ᆒ. Swedberg K, Waagstein F, Hjalmarson A
. Wallentin
I . Prolongation of
survival in congestive cardiomyopathy by beta-receptor blockade . Lancet
1979:1 :1374-6.
31
. Engelmeier RS, O'Connell JB . Walsh R, et al
. Improvement in symptoms
and exercise tolerance by metoprolol in patients with dilated cardiomy-
opathy : a double blind, randomized, placebo-controlled trial . Circulation
19&5,72 :5,%-46
.
32, Camici P . Ferrannini E, Opie LH . Myocardial metabolism in ischemic
heart disease: basic principles and application to imaging by positron
emission tomography
. Prog Cardiovasc Dis 1989,32
:217-38 .
33 . Syrota A
. Positron emission tomography
: evaluation of cardiac receptors.
In : Marcus ML, Skorton DJ, Schelbert HR, Wolf GL, editors. Cardiac
Imaging: A Companion to Braunwald's Heart Disease . Philadelphia:
Saunders, 1991
:1256-7ᆒ.
34. Affolter H. Hertel C, Jaeggi K. Portenier M, Staehelin M . (-)-S-[IHICGP-
12177 and its use to determine the rate constants of unlabeled P-adrencrgic
antagonists. Proc Nall Acad Sci 1985,82:925-9.
35
. Staehelin M, Hertel C
. ('H)CGP-12177 : a P-adrenergic ligand suitable for
measuring cell surface receptors . J Receptor Res 1983 ;3:35-43 .
36. Tsuchihashi H, Yokoyama H, Nagatomo T.
Binding characteristics of
'H-CGP 12177 to P-adrenoceptors in rat myocardial
membranes
. Jpn J
Pharmacol 1989 , 49 :11-9.
37 . Van Waarde A, MeederJG, Blanksma PK, et al. Suitability of CGP-12177
and CGP-265ᆒ5 for quantitative imaging o
.' Padrenoceptors . Nucl Med
Not 1"1,19
:711-8 .
38 . Luthra SK, Osman S, Steel CJ, et al. Comparison of S-["CICGP 12177
metabolism in rat, dog and man using solid phase extraction
and HPLC
[abstract] . J Label Compd Radiopharm 1993;32 :5ᆒ4-5.
39 . Murphree SS, Saffitz JE. Distribution of P-adrenergic receptors in failing
human myocardium: implications for mechanisms of downregulation .
Circulation 1989,79:1214-25 .
4ᆒ . Lentner C, editor
. Geigy Scientific Tables . Vol 1 . Basel, Switzerland :
Ciba-Geigy
.1981 :219
